RayOne EMV is a truly non-diffractive IOL which does not use light splitting technology like many IOLs which increase depth of focus, resulting in low levels of dysphotopsia, similar to standard monofocal lenses.1
RayOne EMV is the only patented aspheric IOL that induces controlled positive spherical aberration to slightly extend the depth of focus.
Compared to a lens with zero spherical aberration, the carefully controlled positive spherical aberration induced by RayOne EMV spreads light along the visual axis.
Centre region
Induced positive spherical aberration
Blended edge region
Reduced longitudinal spherical aberration designed to maintain visual acuity and constrast sensitivity under mesopic conditions.
Since the launch of RayOne EMV in 2020, real world clinical data from across Europe has demonstrated that:
• RayOne can provide spectacle independence for distance and intermediate vision.2
• RayOne EMV provides improvement in intermediate vision without compromising binocular distance vision.2,3,4
• Contrast sensitivity levels similar to standard monofocals in both photopic and mesopic conditions.5
The following clinical results are from a prospective, single-center, observational, noncomparative study conducted at San Carlos Hospital, Madrid, Spain. The study aimed to evaluate visual and refractive outcomes, as well as patient satisfaction, following bilateral implantation of RayOne EMV (IOL) in 50 eyes, with emmetropia as the target refraction.4
Outcomes reveal excellent binocular CDVA and good DCIVA, with a high level of patient satisfaction.4
Comparative outcomes with RayOne EMV
At the Hospital da Luz Lisboa in Lisbon, Professor Filomena Ribeiro and Professor Tiago Ferreira led a 150 patient double-arm, non-randomised prospective case series where RayOne EMV demonstrated excellent visual outcomes for distance and intermediate vision, and good visual acuity for near vision.5
RayOne EMV versus TECNIS Eyhance
At the Hospital San Rafael in Madrid, 22 eyes of 11 patients were implanted with RayOne EMV and 70 eyes of 35 patients implanted with TECNIS Eyhance (Johnson & Johnson Vision). Bilateral emmetropia was targeted for all patients. The defocus curve reports the binocular vision obtained using the best distance correction.6
PRECAUTION: The safety and effectiveness of the RayOne EMV (RAO200E) has not been substantiated in clinical trials. The effects of the RayOne EMV IOL optical design on quality of vision, contrast sensitivity, and subjective visual disturbances (glare, halo, etc.) have not been evaluated clinically. Certain lab-based testing of the RayOne EMV IOL may aid surgeons in understanding the theoretical image quality expected with the RayOne EMV IOL compared to other Rayner FDA approved lenses, but such testing does not fully assess all aspects of clinical difficulties under all conditions. You must discuss with your surgeon the potential benefits of the modified optical design of the RayOne EMV IOL against the potential for risks associated with a degradation in vision quality and the lack of clinical data to characterize the impact of the RayOne EMV IOL optical design on contrast sensitivity and subjective visual disturbance. These considerations may be especially relevant to patients with certain preexisting ocular conditions (prior eye surgery, irregular corneal astigmatism, severe corneal dystrophy, macular disease, optic nerve atrophy, etc).
CAUTION: United States Federal Law restricts this device to sale and distribution by or on the order of a physician and its use is restricted to a properly licensed physician. Published by Rayner.
